[PDF] Projet scientifique Stéphane Dalle - [ Translate this page ]File Format: PDF/Adobe Acrobat - View as HTML
cellulaires impliqués dans le " croisement " entre la voie de signalisation cAMP -PKA utilisée par les récepteurs du glucagon. et du GLP-1 (RCPGs) et la voie ...
www.languedoc-roussillon.inserm.fr/lr/fr/region/organisatio... - Similar pages
IGF - Equipe S. Dalle - [ Translate this page ]Étude des « croisements » des voies de signalisation entre les récepteurs à activité tyrosine-kinase et les récepteurs couplés aux protéines G dans les ...
www.igf.cnrs.fr/equipes/neuro06/projet.php

--------------------------------------------------
Note added at 19 mins (2009-01-22 17:20:55 GMT)
--------------------------------------------------

Growth factor pathway switching: implications for the use of gefitinib and trastuzumab

--------------------------------------------------------------------------------
H. E. Jones a1c1, J. M. W. Gee a1, I. R. Hutcheson a1 and R. I. Nicholson a1
a1 Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, UK.

Article author query
jones he [Google Scholar]
gee jm [Google Scholar]
hutcheson ir [Google Scholar]
nicholson ri [Google Scholar]



Abstract

Over-expression or aberrant signalling of the erbB family members epidermal growth factor receptor (EGFR) and HER2 (erbB2/neu) have been associated with the pathogenesis of the malignant phenotype. In addition, high levels of EGFR and HER2 expression have been shown to correlate with poor prognosis and also implicated in disease progression. Signal transduction inhibitors (STIs) have been developed with specifically target these receptors and include the small molecule tyrosine kinase inhibitor gefitinib (IressaTM) which targets the EGFR and the humanised monoclonal antibody trastuzumab (HerceptinTM), which has anti-tumour activity against HER2. Studies however, have indicated that de novo or acquired resistance to these agents is a major clinical problem. Cancer cells are highly adaptive and can readily switch from one receptor signalling pathway to another in order to maintain growth or cell survival, a process paradoxically, that in many instances is induced by the anti-tumour agents themselves, ultimately limiting their activity and promoting resistance. Evidence is accumulating which demonstrates that signalling interplay occurs between the EGFR/HER2 and the insulin-like growth factor -1 receptor (IGF-1R) and the article will focus on the growth factor pathway switching that occurs between these receptors which can influence the effectiveness gefitinib and trastuzumab.



--------------------------------------------------
Note added at 23 mins (2009-01-22 17:25:30 GMT)
--------------------------------------------------

Non, oubliez "croisement" - ce n'est pas les voies de signalisation qui se croisent, ce sont les cellules cancéreuses qui sont capables de changer de voie.

--------------------------------------------------
Note added at 14 hrs (2009-01-23 07:48:52 GMT)
--------------------------------------------------

This paper was published in 2006. It is not "old".

http://erc.endocrinology-journals.org/cgi/reprint/13/Supplem...

Pathway switching between the EGFR and
IGF-1R: implications for gefitinib therapy

The phenomenon of growth factor pathway switching
from one pathway to another has an adaptive component
which may be induced by virtue of blocking the
dominant ***growth factor receptor pathway***. Indeed,
early work in our laboratory indicated that blockade of
EGFR signalling resulted in the enhancement of the
growth promoting effects of the peptide growth factor
ligands basic fibroblast growth factor and IGF-I in
DU145 and PC-3 human prostate cancer cells respectively
(Jones et al. 1997).